Posted by Michael Wonder on 06 Mar 2024
FDA approves inotuzumab ozogamicin for paediatric patients with acute lymphoblastic leukaemia
6 March 2024 - Today, the FDA approved inotuzumab ozogamicin (Besponsa, Pfizer) for paediatric patients 1 year and older with relapsed or refractory CD22 positive B-cell precursor acute lymphoblastic leukaemia.
Efficacy was evaluated in a multi-centre, single-arm, open-label study in 53 paediatric patients 1 year and older with relapsed or refractory CD22 positive B-cell precursor acute lymphoblastic leukaemia.
